Real-world effectiveness of omalizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP): findings from CHRINOSOR

Rhinology Journal 2026

View at publisher
Authors: Tina Josefin Bartosik, S F Seys, Joost de Kinderen, M Wagenmann, Martin Bruch, Alexandros Andrianakis, Xavier González-Compta, V. Hox, L Pardo Muñoz, S Schneider, Giulia Bettio, M. Burian
+10 more Julia Eckl-Dorna, M Golet Fors, Gert Mariën, Christina Morgenstern, K Scheckenbach, P-V Tomazic, A Tu, S Allu, Zuzana Diamant, C Bachert
DOI: 10.4193/rhin25.514
Cited by: 1

Abstract

Omalizumab is a recombinant DNA-derived humanized monoclonal antibody targeting free immunoglobulin E. In the omalizumab phase III studies for chronic rhinosinusitis with nasal polyp (CRSwNP), a clinically relevant reduction of the nasal polyp score (NPS) was observed leading to improved SinoNasal Outcome Test-22 (SNOT-22). In the extension study, sustained or further improvement of symptoms and NPS reduction were observed up to 52 weeks. Real-world data is needed to establish effectiveness in uncontrolled severe CRSwNP, but so far, data on long-term omalizumab treatment is sparse .

Fields of Study & Subjects

Sinusitis and nasal conditions Allergic Rhinitis and Sensitization Cystic Fibrosis Research Advances

Publication details

Journal / source
Rhinology Journal
Publisher
Stichting Nase
Volume
0
Issue
0
Publication date
1 February 2026
Language
EN